INTRODUCTION {#S1}
============

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the end of 2019 onwards \[[@ref1], [@ref2]\] has probably marked a new milestone in the history of Medicine, that of finding in the shortest time the best understanding of a new infection of unprecedented populational dimension. While in most instances the clinical picture resembles a common cold \[[@ref3]\], around 15% of infections progress to severe pneumonitis and acute respiratory distress syndrome (ARDS) \[[@ref4]\]; later this may lead to septic shock, and coagulation dysfunction \[[@ref5]\]. Diagnosis of SARS-CoV-2 infection is crucial for medical and public health reasons, to allow best treatment of cases and best control of the pandemic. Availability of diagnostic tools is key to provide optimal treatment to infected individuals, to indicate isolation measures to cases and to monitor the efficacy of public health measures \[[@ref6]-[@ref8]\]. Direct detection of viral RNA by RT-PCR was soon developed, and mostly used for the diagnosis of SARS-CoV-2 infectious disease (COVID-19) and is the gold standard in symptomatic patients in medical facilities \[[@ref9]\]. Among its limitations are false negatives from the first week, the need for technology, time and cost. Efficacy of social distancing measures during escalation and de-escalation periods needs close monitoring of novel COVID-19 cases. It is estimated that as high as 50 to 75% of infections may be asymptomatic \[[@ref10]\], and these carriers have been described as effective SARS-CoV-2 shedders \[[@ref11]\].

The rapid lateral-flow point-of-care antibody tests are simple, cheap, and fast. They do not require qualified personnel for interpretation and could be done in primary care. These tests may be optimal to study the prevalence of viral infections, as asymptomatic subjects and infections after viral RNA clearance may both be detected. Serology analysis can also correlate with the clinical severity of COVID-19 if neutralizing antibodies are assessed \[[@ref12]\], although other immune pathways as T-cell response or cytokines may also be implicated in clinical recovery. The main objective of this study was to analyze the accuracy of a point-of-care SARS-CoV-2 IgM and/or IgG rapid test for the diagnosis of COVID-19, and to correlate this pattern of immune response with the severity of disease.

MATERIAL AND METHODS {#S2}
====================

**Study setting, context and design**. This was a transversal study carried out during the third week of confinement in Spain in a field-Hospital enabled in IFEMA (Ferial Institution of Madrid, Spain) with an occupation over 1,400 beds and full spectrum of COVID-19 severity. The project was approved by the Centre's clinical research ethics committee.

**Sample collection and testing**. Anti-SARS-CoV-2 tests were performed to 35 randomly selected SARS-CoV-2 RT-PCR confirmed patients, admitted to IFEMA Field-Hospital between April 27th and April 29th, 2020. COVID-19 diagnosis had been established in all cases based on positive SARS-CoV-2 positive

RT-PCR for pharyngeal swabs. Additionally, 5 healthy volunteers with no history of COVID-19 symptoms and negative SARS-CoV-2 RT-PCR were enrolled as negative controls. Blood samples were obtained by peripheral venipuncture at the elbow flexure. The test was performed according to the manufacturer's recommendations: firstly adding 10 μL of total blood in each well (IgM or IgG) from the EDTA blood tube and then adding 60 μL of the sample diluent to the corresponding well. A picture of every rapid test was taken at the manufacturer's stablished time of reading. Test results were evaluated by two operators. In case of disagreement, a third operator was requested. According to the manufacturer instructions, IgG band reading rendered either negative or positive results. On the other hand, IgM band was classified as either negative, positive or weak positive depending on the intensity of the band staining. IgM positive, IgG positive and either IgM or IgG positive band staining were counted as positive results for the rapid test.

**Severity disease categorization**. Depending on the clinical features of SARS-CoV-2 diseases, the patients were categorized into mild, moderate, severe or critical \[[@ref13]\]. Mild COVID-19: low grade fever, cough, malaise, rhinorrhea, sore throat with or without hemoptysis, nausea, vomiting, diarrhea, but without any radiological features of pneumonia and absence of mental changes. Moderate COVID-19: fever, respiratory symptoms including dry cough and shortness of breath that may emerge along with the radiological features. Severe COVID-19: dyspnea, respiratory frequency 30/minute, blood oxygen saturation 93%, PaO2/FiO2 ratio \<300, and/or lung infiltrates \>50% of the lung field within 24-48 h. Critical COVID-19: usually develops after 7 days in patients with mild/moderate/severe COVID-19 with features of acute respiratory distress syndrome (ARDS) requiring mechanical ventilation along with presence of multiorgan dysfunction failure, metabolic acidosis and coagulation dysfunction.

**Serology rapid test**. The anti-SARS-CoV-2 lateral flow qualitative immunochromatography rapid tests (Autobio Diagnostics Co. Zhengzhou, China) is based on a one-step capture method. The Cassette contains membranes which are pre-coated with two murine anti-human monoclonal antibodies (anti-IgG and anti-IgM) on two separated test lines. SARSCoV-2 recombinant spike protein antigen reagents which can specifically bind to SARS-CoV-2 antibodies (IgM and/or IgG), are bound to colloidal gold and sprayed on conjugation pads. When the sample is applied to the test wells, antibody and labeled antigen complexes are formed and travel up the strip. The labeled gold colorimetric reagent is used to form a visible red/ pink line. The presence of anti-SARS-CoV-2 IgM and/or IgG will be indicated by a visible red/pink test line (T) in the IgM and IgG result windows. Anti-SARS-CoV2 IgM antibodies are bound on the IgM line, and anti-SARS-CoV-2 IgG antibodies are bound to the IgG line. The control (C) line appears in each result window when sample has flowed through the strip. The manufacturer has performed cross-reactivity tests using serum samples containing antibodies to other pathogens, including endemic human CoV, with no IgM or IgG false positive results observed. Across studies, positive and negative percent agreement for the test were 85-88% and 99%, respectively (<https://www.fda.gov/media/137367/download>).

RESULTS {#S3}
=======

A total of 40 individuals were subjected to the anti-SARSCoV-2 rapid test. The sample included 17 (42.5%) men and 23 (57.5%) women, with a mean age of 56.8 years (SD: 10.5). Of the 40 individuals studied, 35 (87.5%) suffered from COVID-19, confirmed by means of a SARS-CoV-2 positive PCR. In every case, the lateral flow test was able to detect an IgG positive band. As expected, the lateral flow test produced a negative result for both IgM and IgG bands in all 5 control cases.

In 31 (88.6%) of the COVID-19 cases studied, bilateral pneumonia was diagnosed by means of chest radiology and/ or CT Scan. A total of 12 (34.3%) COVID-19 cases were categorized as mild or moderate, whereas 23 (65.7%) were categorized as severe or critical. The average time from the first day of reported symptoms to the lateral flow test were 28 days (SD: 8.7). The ranges were similar between the mild-moderate cases (minimum: 17 days; maximum: 45 days) and the severe-critical (minimum: 16 days; maximum: 48 days).

Among the 35 COVID-19 cases registered, 5 (14.3%) were clearly positive for both IgM and IgG bands, 21 (60%) were weakly positive for IgM and positive for IgG, and none were negative for both IgG and IgM. No cases of a positive IgM band together with a negative IgG band were observed ([figure 1](#F1){ref-type="fig"}). A remaining total of 9 (25.7%) COVID-19 cases presented a positive IgG band in the lateral flow test with a negative IgM band result, regardless of them being mild-moderate (5; 14.3%) or severe-critical (4; 11.4%) ones.

![IgM band readings observed in COVID-19 patients regarding severity of the disease and number of days since first symptom was reported.\
**NEG: negative; POS: positive; w pos: weak positive**.](revespquimioter-33-258-g001){#F1}

![IgG band readings observed in COVID-19 patients regarding severity of the disease and number of days since first symptom was reported.\
**POS: positive**.](revespquimioter-33-258-g002){#F2}

![Example of results in anti-SARS-CoV-2 lateral flow qualitative immunochromatography rapid tests Autobio Diagnostics Co. Zhengzhou, China](revespquimioter-33-258-g003){#F3}

Regarding the IgM band staining, the positive result was observed more frequently among the severe-critical cases (4; 11.4%) than in the mild-moderate ones (1; 2.9%). Among the 21 patients with weak IgM positive results 15 were severe-critical cases (42.9%) and 6 were mild-moderate cases (17.1%). IgM response was more durable in severe-critical cases (mean: 29.7 days; SD: 8.4) as compared with moderate cases (mean: 21.2 days; SD: 2.0). Moreover, in mild-moderate cases, weak positive IgM result was not observed beyond the 25th day of symptoms. In the case of the severe-critical cases, the weak positive IgM result appeared throughout the whole range of symptomatic days. For mild-moderate COVID-19 cases, positive IgG band appeared mostly around day 20 of symptoms (mean: 26.3 days; SD: 9.6). In the severe-critical cases, positive IgG band spanned more uniformly (mean: 28.9 days; SD: 8.3). All results are summarized in [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and graphically depicted in [figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. [Figure 3](#F3){ref-type="fig"} shows three Rapid Tests displaying an example of each possible positive result observed in our study.

###### 

Main characteristics of the sample.

  N    Sex      Age   RT-PCR   IgM     IgG   Severity of disease   Days of symptoms
  ---- -------- ----- -------- ------- ----- --------------------- ------------------
  1    Female   53    POS      w pos   POS   Severe                24
  2    Female   54    POS      w pos   POS   Critical              27
  3    Female   73    POS      NEG     POS   Severe                26
  4    Female   49    POS      NEG     POS   Moderate              17
  5    Female   54    POS      NEG     POS   Severe                41
  6    Female   74    POS      w pos   POS   Severe                40
  7    Female   40    POS      w pos   POS   Moderate              18
  8    Female   60    POS      w pos   POS   Severe                37
  9    Male     71    POS      POS     POS   Moderate              23
  10   Male     65    POS      POS     POS   Severe                37
  11   Male     77    POS      w pos   POS   Severe                31
  12   Male     47    POS      w pos   POS   Severe                23
  13   Male     57    POS      w pos   POS   Severe                30
  14   Male     51    POS      w pos   POS   Severe                18
  15   Male     68    POS      w pos   POS   Severe                28
  16   Male     57    POS      w pos   POS   Moderate              20
  17   Female   70    POS      w pos   POS   Severe                19
  18   Female   56    POS      NEG     POS   Moderate              24
  19   Female   61    POS      w pos   POS   Severe                29
  20   Female   66    POS      NEG     POS   Severe                19
  21   Female   54    POS      POS     POS   Severe                25
  22   Female   59    POS      w pos   POS   Moderate              22
  23   Female   62    POS      w pos   POS   Moderate              22
  24   Female   67    POS      NEG     POS   Severe                26
  25   Male     52    POS      POS     POS   Severe                16
  26   Male     74    POS      w pos   POS   Severe                48
  27   Male     58    POS      w pos   POS   Severe                40
  28   Female   42    POS      w pos   POS   Mild                  24
  29   Male     60    POS      w pos   POS   Critical              26
  30   Male     59    POS      w pos   POS   Moderate              21
  31   Female   54    POS      POS     POS   Severe                30
  32   Female   45    POS      w pos   POS   Severe                25
  33   Female   58    POS      NEG     POS   Moderate              35
  34   Female   45    POS      NEG     POS   Mild                  44
  35   Male     45    POS      NEG     POS   Mild                  45
  36   Female   30    NEG      NEG     NEG   Negative control      
  37   Male     54    NEG      NEG     NEG   Negative control      
  38   Male     61    NEG      NEG     NEG   Negative control      
  39   Female   41    NEG      NEG     NEG   Negative control      
  40   Male     49    NEG      NEG     NEG   Negative control      

RT-PCR: real time-polimerase chain reaction; POS: positive; NEG: negative; w pos: weak positive.

###### 

RT-PCR and rapid test results in studied sample, including sensitivity and specificity calculated for the Rapid Test.

                                    RT-PCR positive   RT-PCR negative
  --------------------------------- ----------------- -----------------
  IgM negative/ IgG negative        0                 5
  IgM positive/ IgG negative        0                 0
  IgM weak positive/ IgG positive   21                0
  IgM positive/ IgG positive        5                 0
  IgM negative/ IgG positive        9                 0
  Total                             35                5
  Sensitivity                       100%              
  Specificity                                         100%

RT-PCR: real time-polimerase chain reaction.

DISCUSSION {#S4}
==========

The usefulness of rapid tests for the diagnosis of active COVID-19 has been questioned regarding their inferiority when compared to the RT-PCR testing. Some authors think it should not be used for triage, diagnosis, individual risk assessment or public health decisions \[[@ref14]\]. In that context, suboptimal levels of rapid test's sensitivity have been attributed by some authors to delayed humoral responses. Studies showed that, normally, seroconversion occurred sequentially for IgM and then IgG with a median time of 11 and 14 days, respectively \[[@ref15]\]. Another limitation of serological tests may come from the differences in individual antibody production, that could render false-negative results \[[@ref16]\]. It has been shown that during the early stages of the disease, the SARS-CoV-2 heavily proliferates at the nasopharyngeal area, rendering the RT-PCR a better option for detection. But, at more advanced stages, the lower respiratory or intestinal tract may be infected, representing the epicenter of viral replication. Thus, the nasopharyngeal swab may not be the best sampling method for all the stages of the disease \[[@ref17]-[@ref20]\].

Although, strictly, lateral flow tests can only provide qualitative (positive/negative) results, considering the weak positive result on the IgM band, could render an extra information useful when combined with the disease severity. This division may correlate with the three different types of antibody responses (strong, weak and non-response) identified by other authors in COVID-19 patients by means of ELISA assays \[[@ref21]\], or it may represent a form of prozone effect when high titers of IgM are present. As a matter of fact, studies on lateral flow immunochromatographic strip tests have showed that the prozone effect may be the cause for weak/faint readings on this kind of tests, especially in undiluted samples such as those used in our work \[[@ref22], [@ref23]\]. Finding in our series that also weak IgM bands were more frequently present in patients with more severe COVID-19 supports this hypothesis, although further studies are needed. In that sense, although serological ELISA assays still represent a superior alternative to the quantitative analysis of antibody titers, they are less available and more complex to perform as a point-of-care or community-based diagnostic strategy.

In comparison with RT-PCR, lateral flow immunoassays detecting IgM and IgG against SARS-CoV-2 can detect patients at different infection stages. In fact, some authors believe rapid tests based on IgM-IgG detection could provide valuable information on the COVID-19 time-course \[[@ref16]\]. Nevertheless, infection time point based on how long each patient was infected or for how long each patient had symptoms is fundamental to correctly outline the infection time course for a single patient. In our study, we registered the time from the first day of reported symptoms until the rapid test was performed. In this context we observed a more durable IgM response in more severe COVID-19 cases, while mild-moderate cases did not show positive IgM results beyond day 25 of symptoms. This finding could be related to faster viral clearance in patients with benign outcome, or with IgM persistence indicative of more intense inflammatory response leading to respiratory distress.

Despite extensive clinical experience suggests that mild and moderate COVID-19 cases may have shorter symptomatic periods than severe or critical ones, in our sample we observed similar ranges between both groups (17-45 days vs. 16-48 days). The fact that we did not include any patient with early (\<7 days) or intermediate (8-15 days) disease stage may account for the high sensitivity and specificity observed in our study. In fact, several studies have already reported low positive rates for both IgM and IgG during the first 7 days of illness. Those rates dramatically increased 15 days after onset of symptoms \[[@ref15], [@ref18]\].

The quality and quantity of antibodies produced against a specific virus may condition the final immunological response \[[@ref24]\]. For example, Tan et al. \[[@ref21]\] have reported an association between more severe forms of COVID-19 and higher titers of IgM. This same study has also showed that IgM levels remained positive for longer periods in severe COVID-19 cases. Similarly, we found that patients with more severe respiratory compromise had longer anti-S IgM production, as detected with the rapid test. Neutralizing antibodies can block viral entry, fusion or egress, therefore easing the course of the infection. However, a phenomenon known as antibody-dependent enhancement (ADE), may boost inflammation and tissue damage by activating phagocytes via Fc region receptors. This phenomenon has been documented for SARS-CoV and may be suggested in SARS-CoV-2 infection according to our observations. Furthermore, *in vitro* studies suggest that ADE occurs in phagocytes expressing Fc receptors when antibodies remain at a low concentration, whereas higher antibody titers effectively block viral entry \[[@ref25]\]. Other studies suggest that high-affinity antibodies exert better neutralization and protection. Apparently, ADE is induced when the antibody-antigen interaction strength is below the threshold for neutralization \[[@ref26]\]. It is important to recall that IgM is a strong pro-inflammatory immunoglobulin that efficiently activates complement. Some authors have described strong IgM responses as independent factors associated with disease severity \[[@ref21]\]. Relevantly, ADE in macrophages leads to an intense production of TNF and IL-6 \[[@ref27]\]. Those cytokines have been held responsible for the potent immune inflammatory response elapsed by SARS-CoV-2 in the lung, and inflammation have been closely related to severity of COVID-19 \[[@ref28]\]. Therefore, several therapeutic approaches currently used to mitigate COVID-19, such as tocilizumab or infliximab, are based on their blockade \[[@ref29], [@ref30]\].

Regarding SARS-CoV, studies reported association between severe forms of the disease and a more robust IgG response, namely by and earlier seroconversion and higher antibody titers \[[@ref31]\]. Recent studies in patients with COVID-19 have identified potentially detrimental effects of certain antibody responses in some patients. Jiang et al. \[[@ref32]\] found a correlation between IgG response and COVID-19 severity. Nevertheless, that correlation was not directly stablished, but by means of its subordination to LDH levels. Moreover, their work stablished a correlation between female gender and younger ages with stronger IgG responses, even though higher mortality rates have been identified in aged male patients \[[@ref33]\]. In our study, a positive IgG band appeared mostly around day 20 of symptoms for mild-moderate cases, whereas it spanned more uniformly in the severe-critical ones. Two likely explanations may account for that observation. First, mild and moderate cases tend to display shorter clinical courses and, therefore, is logical that seroconversion would have occurred sooner. Second, the fact that in our sample the severe and critical cases predominated, may have smoothed the distribution of the data. Probably if more mild-moderate cases would have been included, both distributions would look rather similar ([figure 2](#F2){ref-type="fig"}).

Lymphopenia has been widely reported as a key laboratory finding in COVID-19 cases \[[@ref34]-[@ref36]\]. It may be the result of direct T-cell apoptosis induction by the SARS-CoV-2 \[[@ref37]\] or induced by the pro-inflammatory cytokines released in the context of a "cytokine storm" \[[@ref38]\]. Specifically, CD4+ and CD8+ T-cell depletion have been more frequently observed in the more severe cases \[[@ref34], [@ref39]\]. CD4+ T-cells stimulate B-cells to produce antibodies, and CD8+ T-cells directly eliminate virus-infected cells \[[@ref37]\]. Moreover, CD8+ T-cells have been reported to function as T follicular helper (Tfh) cells in the germinal center of the B-cell follicle in the context of infection. By expressing B-cell co-stimulatory proteins they may have a role in promoting B-cell differentiation and antibody isotype class switching \[[@ref40]\]. Those findings suggest that an incomplete or lagged isotype change from IgM to IgG may be more frequent among severe-critical COVID-19 cases, which is again in line with the results of the present study. More studies regarding the different patterns of isotype switching according to the severity of the disease would be of great use to shed some light on the immunological fingerprint of COVID-19. The selection of targeted therapies or the development of new immunomodulating agents could benefit from this approach up to an extent that we still cannot foresee.

Limitations of our work included a potential source of recall bias, since the first day of reported symptoms ultimately relies on patient recalling after RT-PCR confirmation. That could have altered the accurate application of the already described IgM/IgG dynamics to our particular sample. Another obvious limitation of our study is the reduced sample size. We couldn't dilute the samples for testing either, because we didn't have any more tests. Finally, there is a selection bias in the study, as it is difficult to find patients admitted with mild diseases, however we analyzed them together with patients with moderate clinical behavior, in which respiratory involvement could appear with or without radiological findings. By associating them, two populations were obtained that were more easily comparable to severe and critical patients, who also contributed with parainfectious phenomena such as distress and thrombosis. Even though, such limited size already gave us adequate exploratory information to plan for more ambitious studies in order to confirm the hypothesis raised.

As a conclusion, in late stage (after more than 15 days of symptoms) COVID-19 cases, lateral flow immunochromatography Rapid Tests (such as Autobio Diagnostics Co.) may be useful for diagnosis and clinical management. The weak positive staining for IgM could represent a prozone effect that would act as a surrogate marker for a stronger IgM response. That fact, together with a broader period of detection in patients with more severe COVID-19, could account for a delay in the immunoglobulin isotype switching. Further quantitative studies would be necessary to allow us to correlate the immunoglobulin kinetics with pathocrony and severity of COVID-19 disease.
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